Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial).
Nan ZhouXiaofen LiYu YangSirui TanShunyu ZhangQiyue HuangHongfeng GouPublished in: BMC cancer (2023)
Chinese Clinical Trial Registry ChiCTR2100052118. Registered October 19, 2021.